<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with catastrophic <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) have in common: a) clinical evidence of multiple organ involvement developing over a very short period of time; b) histopathological evidence of multiple small vessel occlusions, and c) laboratory confirmation of the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL), usually in high titre </plain></SENT>
<SENT sid="1" pm="."><plain>Although patients with catastrophic APS represent less than 1% of <z:hpo ids='HP_0000001'>all</z:hpo> patients with APS, they are usually in a life-threatening situation </plain></SENT>
<SENT sid="2" pm="."><plain>The rarity of this syndrome makes it extraordinarily difficult to study in any systematic way </plain></SENT>
<SENT sid="3" pm="."><plain>In order to correlate <z:hpo ids='HP_0000001'>all</z:hpo> the published case reports as well as newly diagnosed cases from <z:hpo ids='HP_0000001'>all</z:hpo> over the world, an international registry of patients with catastrophic APS (CAPS Registry) was created in 2000 by the European Forum on aPL </plain></SENT>
<SENT sid="4" pm="."><plain>Currently, it documents the clinical, laboratory and therapeutic data of more than 400 patients and can be consulted through Internet at www.med.ub.es/MIMMUN/FORUM/CAPS.HTM </plain></SENT>
<SENT sid="5" pm="."><plain>The analysis of this registry has allowed the characterization of the clinical and laboratory features of the catastrophic APS as well as the establishment of preliminary criteria for its classification and guidelines for its management </plain></SENT>
</text></document>